EASL – The Digital International Liver Congress 2020

Published on 26/08/2020

August 27-29, 2020
Digital congress

ENYO Pharma was connected from the 27th to the 29th of August at the digital EASL International Liver Congress and present 2 posters.

“Characterization of EYP001 a novel, potent and selective FXR agonist in in vitro 3D human liver models”

“A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis”

Read next in 'Events'

• ASN Kidney Week 2024
• ASN Kidney Week 2024
• Alport Connect 2024, the annual Alport syndrome patient and family meeting in US
• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport